Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 2/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116396 | 0.91 | ADRB3 (0.63) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7116378 | 0.91 | ADRB3 (0.63) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7115594 | 0.90 | ADRB3 (0.62) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7115609 | 0.90 | ADRB3 (0.62) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7115615 | 0.90 | ADRB3 (0.62) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7123781 | 0.88 | ADRB3 (0.61) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7122878 | 0.87 | ADRB3 (0.60) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL7114588 | 0.86 | ALDH1A1 (0.48) | ADRB3S1PR1PLA2G4BS1PR4S1PR3 | |
| SCHEMBL7114253 | 0.84 | ADRB3 (0.57) | ADRB3ALDH1A1CYP1A2CYP2D6MAPT | |
| SCHEMBL16682325 | 0.83 | KCNH2 (0.49) | ADRB3S1PR1S1PR4S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-6465501-B2 | USEFUL IN TREATING OR INHIBITING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA, ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, GLAUCOMA, OCULAR HYPERTENSION AND INCONTINENCE | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-14 | — | — | US | disclosed |
| WO-2002006258-A1 | AZOLIDINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885S1PR1 673/4885PLA2G4B 3416/4885 |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885S1PR1 673/4885PLA2G4B 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.